101 related articles for article (PubMed ID: 10965448)
1. [Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer].
Awakura Y; Yamamoto M; Fukuzawa S; Itoh N; Nonomura M; Fukuyama T
Hinyokika Kiyo; 2000 Jul; 46(7):449-52. PubMed ID: 10965448
[TBL] [Abstract][Full Text] [Related]
2. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
Khil MS; Kim JH; Bricker LJ; Cerny JC
Cancer J Sci Am; 1997; 3(5):289-96. PubMed ID: 9327153
[TBL] [Abstract][Full Text] [Related]
3. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
5. [Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center].
Zufferey L; Roques B; Fléchon A; Droz JP
Bull Cancer; 2001 Dec; 88(12):1213-21. PubMed ID: 11792613
[TBL] [Abstract][Full Text] [Related]
6. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
[TBL] [Abstract][Full Text] [Related]
7. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
Hudes G; Einhorn L; Ross E; Balsham A; Loehrer P; Ramsey H; Sprandio J; Entmacher M; Dugan W; Ansari R; Monaco F; Hanna M; Roth B
J Clin Oncol; 1999 Oct; 17(10):3160-6. PubMed ID: 10506613
[TBL] [Abstract][Full Text] [Related]
8. [Prostate cancer with penile metastasis: a case report].
Sawada A; Segawa T; Nakanishi S; Kinoshita H; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2005 Nov; 51(11):771-3. PubMed ID: 16363713
[TBL] [Abstract][Full Text] [Related]
9. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
10. Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Schmidt U; Bilkenroth U; Linné C; Fuessel S; Kraemer K; Froehner M; Wirth MP; Meye A
Int J Oncol; 2004 Jun; 24(6):1393-9. PubMed ID: 15138579
[TBL] [Abstract][Full Text] [Related]
11. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Arah IN; Dixon SC; Horti J; Figg WD
Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
[TBL] [Abstract][Full Text] [Related]
12. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
[TBL] [Abstract][Full Text] [Related]
13. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
Kobayashi M; Kuramoto H; Ota J; Fujimoto N
Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
[TBL] [Abstract][Full Text] [Related]
14. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
15. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
[TBL] [Abstract][Full Text] [Related]
16. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
[TBL] [Abstract][Full Text] [Related]
17. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of hormone-refractory prostate cancer with estramustine phosphate].
Morote J; López-Pacios MA; Ahmad A; Vila J; de Torres JA
Actas Urol Esp; 1991; 15(5):421-4. PubMed ID: 1725472
[TBL] [Abstract][Full Text] [Related]
20. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
